Natera to Present New Renasight Data at ASN Kidney Week 2024
Natera (NASDAQ: NTRA) will present new data on its 385-gene kidney genetic test, Renasight™, at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego from Oct. 23-27. The company and collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD).
This includes an updated analysis from the prospective RenaCARE study and additional data on the utility of genetic testing for CKD patients. The presentations align with recent support for renal genetic testing from organizations like NKF, KDIGO, and The New England Journal of Medicine.
Dr. Anthony Bleyer of Wake Forest University School of Medicine highlighted that 25% of dialysis patients don't know their kidney disease cause, emphasizing the importance of genetic testing. Natera's presentations will cover topics such as patient satisfaction with genetic counseling, genetic testing results in African American patients, and the genetic landscape of glomerular disease and FSGS.
Natera (NASDAQ: NTRA) presenterà nuovi dati sul suo test genetico dei reni a 385 geni, Renasight™, alla American Society of Nephrology (ASN) Kidney Week 2024 a San Diego dal 23 al 27 ottobre. L'azienda e i collaboratori presenteranno 7 abstract incentrati su test genetici completi per pazienti con malattia renale cronica (MRC).
Questo include un'analisi aggiornata dello studio prospettico RenaCARE e ulteriori dati sull'utilità del test genetico per i pazienti con MRC. Le presentazioni sono in linea con il recente supporto per il test genetico renale da parte di organizzazioni come NKF, KDIGO e The New England Journal of Medicine.
Il dott. Anthony Bleyer della Wake Forest University School of Medicine ha sottolineato che il 25% dei pazienti in dialisi non conosce la causa della propria malattia renale, evidenziando l'importanza del test genetico. Le presentazioni di Natera copriranno argomenti come la soddisfazione dei pazienti con la consulenza genetica, i risultati dei test genetici nei pazienti afroamericani e il panorama genetico delle malattie glomerulari e della FSGS.
Natera (NASDAQ: NTRA) presentará nuevos datos sobre su prueba genética renal de 385 genes, Renasight™, en la American Society of Nephrology (ASN) Kidney Week 2024 en San Diego del 23 al 27 de octubre. La empresa y sus colaboradores presentarán 7 resúmenes centrados en la prueba genética integral para pacientes con enfermedad renal crónica (ERC).
Esto incluye un análisis actualizado del estudio prospectivo RenaCARE y datos adicionales sobre la utilidad de las pruebas genéticas para pacientes con ERC. Las presentaciones están alineadas con el apoyo reciente a las pruebas genéticas renales de organizaciones como NKF, KDIGO y The New England Journal of Medicine.
El Dr. Anthony Bleyer de la Wake Forest University School of Medicine destacó que el 25% de los pacientes en diálisis no conoce la causa de su enfermedad renal, subrayando la importancia de las pruebas genéticas. Las presentaciones de Natera cubrirán temas como la satisfacción del paciente con la asesoría genética, los resultados de las pruebas genéticas en pacientes afroamericanos y el panorama genético de las enfermedades glomerulares y la FSGS.
나테라(Natera) (NASDAQ: NTRA)는 10월 23일부터 27일까지 샌디에이고에서 열리는 미국 신장학회(ASN) 신장주간 2024에서 385유전자 신장 유전자 검사인 Renasight™에 관한 새로운 데이터를 발표할 예정이다. 회사와 협력자들은 만성 신장 질환(CKD) 환자를 위한 포괄적인 유전자 검사에 중점을 둔 7개의 초록을 발표할 것이다.
여기에는 RenaCARE 연구의 업데이트된 분석과 CKD 환자에 대한 유전자 검사의 유용성에 관한 추가 데이터가 포함된다. 이러한 발표는 NKF, KDIGO 및 The New England Journal of Medicine과 같은 기관으로부터 신장 유전자 검사에 대한 최근 지원과 일치한다.
웨이크포레스트 의과대학의 앤서니 블레어 박사는 투석 환자의 25%가 신장 질환의 원인을 모르고 있다고 강조하며 유전자 검사의 중요성을 강조했다. 나테라의 발표는 유전자 상담에 대한 환자의 만족도, 아프리카계 미국인 환자의 유전자 검사 결과, 사구체 질환 및 FSGS의 유전자 환경과 같은 주제를 다룰 것이다.
Natera (NASDAQ: NTRA) présentera de nouvelles données sur son test génétique rénal à 385 gènes, Renasight™, lors de la Semaine du Rein 2024 de l'American Society of Nephrology (ASN) à San Diego, du 23 au 27 octobre. L'entreprise et ses collaborateurs présenteront 7 résumés axés sur les tests génétiques complets pour les patients atteints de maladie rénale chronique (MRC).
Cela inclut une analyse mise à jour de l'étude prospective RenaCARE et des données supplémentaires sur l'utilité des tests génétiques pour les patients atteints de MRC. Les présentations sont en accord avec le soutien récent à l'examen génétique rénal de la part d'organisations telles que la NKF, la KDIGO et le New England Journal of Medicine.
Le Dr. Anthony Bleyer de la Wake Forest University School of Medicine a souligné que 25% des patients sous dialyse ne connaissent pas la cause de leur maladie rénale, soulignant l'importance des tests génétiques. Les présentations de Natera aborderont des sujets tels que la satisfaction des patients avec le conseil génétique, les résultats des tests génétiques chez les patients afro-américains et le paysage génétique des maladies glomérulaires et de la FSGS.
Natera (NASDAQ: NTRA) wird neue Daten zu ihrem 385-Gen-Nierengen-Test Renasight™ auf der American Society of Nephrology (ASN) Kidney Week 2024 in San Diego vom 23. bis 27. Oktober präsentieren. Das Unternehmen und seine Partner werden 7 Abstracts vorstellen, die sich auf umfassende genetische Tests für Patienten mit chronischer Nierenerkrankung (CKD) konzentrieren.
Dies umfasst eine aktualisierte Analyse aus der prospektiven RenaCARE-Studie sowie zusätzliche Daten zur Nützlichkeit genetischer Tests für CKD-Patienten. Die Präsentationen stehen im Einklang mit der aktuellen Unterstützung für genetische Nierentests von Organisationen wie NKF, KDIGO und The New England Journal of Medicine.
Dr. Anthony Bleyer von der Wake Forest University School of Medicine hob hervor, dass 25% der Dialysepatienten die Ursache ihrer Nierenerkrankung nicht kennen, was die Bedeutung genetischer Tests unterstreicht. Nateras Präsentationen werden Themen wie die Patientenzufriedenheit mit genetischer Beratung, die Ergebnisse von genetischen Tests bei afroamerikanischen Patienten und die genetische Landschaft von glomerulären Erkrankungen und FSGS behandeln.
- None.
- None.
Natera and its collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD). This includes an updated analysis from the prospective RenaCARE study, along with additional data on the utility of genetic testing for patients with CKD to enable more precise diagnoses, guide personalized treatment, and improve overall clinical outcomes.
The evidence to be presented at ASN adds to growing support for renal genetic testing, including the recently updated Kidney Diseases Improving Global Outcomes (KDIGO) guideline for the management of CKD, a newly published consensus statement on renal genetics by The National Kidney Foundation (NKF),1,2 and a review article published in The New England Journal of Medicine3 reiterating the clinical utility of genetic testing for the majority of patients with CKD.
“This has been a pivotal year in the field of renal genetic testing, with robust and unified support coming from leading organizations like NKF, KDIGO, and the New England Journal of Medicine on the benefits of comprehensive genetic testing for patients with CKD,” said Anthony Bleyer, MD, MS, professor of nephrology at Wake Forest University School of Medicine. “The reality is that
“We are pleased to present data with our collaborators at ASN that further supports the clinical need for testing alongside these recent recommendations and guideline updates,” said Maggie Westemeyer, MS, CGC, director of clinical genetic services for Organ Health at Natera.
The full list of presentations at ASN Kidney Week include:
Poster Presentation | Abstract # TH-PO526 | Presenter: Meg Hager, MS, MPH, CGC | October 24, 10:00 AM to 12:00 PM PT | Renasight
Patient Satisfaction and Outcomes Following a Session with a Genetic Counselor for Kidney Disease
Poster Presentation | Abstract # FR-PO653 | Presenter: Anthony Bleyer, MD, MS | October 25, 10:00 AM to 12:00 PM PT | Renasight
Results of Genetic Testing with a 385-Gene Panel in African American Patients with Kidney Disease
Poster Presentation | Abstract # FR-PO655 | Presenter: Insa Schmidt, MD, MPH | October 25, 10:00 AM to 12:00 PM PT | Renasight
Genetic testing in biopsy-confirmed kidney disease
Poster Presentation | Abstract # FR-PO658 | Presenter: Maggie Westemeyer, MS, CGC | October 25, 10:00 AM to 12:00 PM PT | Renasight
The RenaCARE Study: Updating Genetic Testing Results in Response to New Gene-Disease Association and Variant Upgrade
Poster Presentation | Abstract # FR-PO659 | Presenter: Maggie Westemeyer, MS, CGC | October 25, 10:00 AM to 12:00 PM PT | Renasight
Fabry Disease Genetic Diagnosis in a Large CKD Population Tested with a Broad Renal Gene Panel
Poster Presentation | Abstract # FR-PO667 | Presenter: Michelle Bloom, PhD | October 25, 10:00 AM to 12:00 PM PT | Renasight
The Genetic Landscape of Glomerular Disease and FSGS among >50,000 Genetically Tested for CKD
Poster Presentation | Abstract # SA-PO578 | Presenter: Dinah Clark, MS, CGC | October 26, 10:00 AM to 12:00 PM PT | Renasight
Assessment of Key Indicators of Pathogenicity in PKD1/2 Variants
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
References
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Stevens, P E, et al. Kidney International. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
- Advancing Genetic Testing in Kidney Diseases: Report from a National Kidney Foundation Working Group. Franceschini, N, et al. American Journal of Kidney Diseases. 2024; doi:10.1053/j.ajkd.2024.05.010
- Vivante A. Genetics of Chronic Kidney Disease. New England Journal of Medicine. 2024;391(7):627-639. doi:10.1056/NEJMra2308577
View source version on businesswire.com: https://www.businesswire.com/news/home/20241020870613/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What new data will Natera present at ASN Kidney Week 2024?
How many abstracts will Natera and its collaborators present at ASN Kidney Week 2024?
What percentage of dialysis patients don't know the cause of their kidney disease, according to Dr. Bleyer?
When and where will ASN Kidney Week 2024 take place?
What topics will Natera's presentations cover at ASN Kidney Week 2024?
